US Stock Insider Trading | Organogenesis disclosed one insider transaction on March 3rd

robot
Abstract generation in progress

On March 3, 2026, Organogenesis (ORGO) disclosed an insider trading activity. Executive Cavorsi Robert sold 700 shares on March 1, 2026.

[Recent Insider Trading]

Disclosure Date Position Name Transaction Date Buy/Sell Quantity Price per Share (USD) Total Amount (USD)
March 3, 2026 Executive Cavorsi Robert March 1, 2026 Sell 700 3.21 2,247.00
February 20, 2026 Director Gillheeney Gary S. February 18, 2026 Sell 90,400 3.84 347,100
February 20, 2026 Executive Francisco David February 18, 2026 Sell 14,500 3.84 5,580
February 20, 2026 Executive Bilbo Patrick February 18, 2026 Sell 16,200 3.84 6,230
February 20, 2026 Executive Montecalvo Antonio S. February 18, 2026 Sell 3,741 3.84 14,400
February 20, 2026 Executive Cavorsi Robert February 18, 2026 Sell 5,432 3.84 20,900
February 20, 2026 Executive Freedman Lori February 18, 2026 Sell 14,300 3.84 54,800
February 20, 2026 Executive Grow Brian February 18, 2026 Sell 11,800 3.84 45,200
February 15, 2026 Executive Cavorsi Robert February 15, 2026 Sell 17,700 3.73 66,000
February 15, 2026 Director Gillheeney Gary S. February 15, 2026 Sell 271,400 3.73 1,012,300

[Company Profile]

Organogenesis Holdings Inc. is a Delaware-based company. It is a leading regenerative medicine company offering a portfolio of biologic and acellular biomaterials products for advanced wound care and surgical biologics (including orthopedics and spine). Organogenesis’s comprehensive product portfolio aims to treat patients with various repair and regeneration needs.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments